Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin biomarker assay were highlighted in two oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback